Portfolio/ External Alliance Manager

KERI L. DORN

Plymouth Meeting, PA Mobile: 484-***-****

*******@*****.*** www.linkedin.com/in/keri-dorn-22b88823 PHARMACEUTICAL LEADER

Lead Pharmaceutical R&D Teams and External Alliance Collaborations Developing Novel Therapeutics through Pre-Clinical Stages Accomplished pharmaceutical professional (15+ years) with a strong track record of leading multi-disciplinary teams in highly matrixed environments. Deliver results-oriented leadership and operational management across functional disciplines and pharmaceutical sectors through portfolio management and facilitation of governance forums. Lead collaborations with external partners and alliance management with CROs. Demonstrate extensive background in pharmaceutical R&D; immune-oncology, biologics research, and vaccine pre-clinical development.

Pharmaceutical R&D Oncology / Immune-Oncology Project Governance Portfolio Management Alliance Management External Asset Evaluation and Acquisition GLP / GMP Environments PROFESSIONAL EXPERIENCE

JANSSEN PHARMACEUTICAL COMPANY OF JOHNSON & JOHNSON 2012 - 2023 Oncology Discovery Portfolio Lead, Oncology Therapeutic Area Remote. 2020 - 2023 Led planning, prioritization, and organization of discovery and early development portfolio through facilitation of governance forums. Oversaw early strategic portfolio management, prioritization, and facilitated decision support. Partnered with Disease Area Stronghold scientific leaders to develop strategies and advance new platforms, modalities, and assets. Managed operational aspects of external asset acquisition and led external alliances with CROs.

• Facilitated expansion of portfolio value by building strategic partnerships, capabilities, and plans.

• Collaborated with project teams and cross-functional leaders, enhancing planning, and removing operational hurdles to boost efficiency and increase portfolio value.

• Identified potential new critical assets along with senior leadership and provided capability build and management of early external strategic alliances. Led internal asset evaluation efforts and oversaw the evolution of new assets through later stage external alliances, managing operational and strategic aspects of projects during development.

• Led the “Return to Work” initiative for the Oncology Therapeutic Area in Spring House, PA during / post global Covid pandemic, implementing tools and online analytics in collaboration with IT and site operations to facilitate re-initiation of on-site activities in compliance with CDC and local / corporate guidelines. Senior Associate Scientist I / II, Oncology Discovery - Immune-Oncology Spring House, PA. 2016 - 2020 Led efforts to generate novel platforms and program data specific to the Immune-Oncology portfolio. Developed a monoallelic HLA APC platform to serve as a screening tool for the Oncology Vaccines group and lead efforts to generate the data package supporting a Prostate Neo-ORF Vaccine patent application. Oversaw several due diligence efforts to evaluate external IO assets and generated data packages to facilitate final decision making and IP generation.

• Performed various immunological cell-based assays with multiple read outs and generated data presentations, to supporting decisions for lead molecules in Immune-Oncology Portfolio.

• Generated slide decks with comprehensive data for contribution to NME transition and presentation to SLT.

• Developed an ex-vivo platform to evaluate IO targets in primary human samples o Managed the acquisition of primary human tumors through several CRO’s. o Identified and vetted CRO’s, communicated specifications for samples, and managed vendor relationship. o Responsible for PO generation, sample acquisition, and PO close out through procurement. o Developed and led a team in the execution of experiments utilizing the platform. o Led collaboration with internal biostatistics to generate global representative data.

• Coordinated department wide flowjo training. Managed PO, coordinated training agenda based on user needs, and determined scheduling for onsite training.

• Served as Immune-Oncology representative on panel for Safety and Lab Training. Trained and coordinated documentation for new lab employees.

• Managed electronic laboratory notebook (ELN) documentation to support experimental contributions from several teams. Created all ELN entries, gathered data from multiple sources and culminated documentation in cyberlab. Ensured compliance with DDI traceability and transparency standards.

KERI L. DORN *******@*****.*** PAGE TWO

JANSSEN PHARMACEUTICAL COMPANY OF JOHNSON & JOHNSON (Continued) Associate Scientist I / II, Biologics Research – Hybridoma Spring House, PA. 2014 - 2016

• Supported the portfolio, target validation, assay development, and technology development through mAb generation utilizing hybridoma platforms and AutoMacs sorting technology.

• Executed biochemical mAb screening assays utilizing Integra ViaFlo, Combi RapidStack, and Integra Assist (automated pipetting) technologies.

Associate Scientist I, Biologics Research - Fc Engineering Spring House, PA. 2012 - 2014

• Generated technical reports and contributed data for patents for novel molecules.

• Performed target research in collaboration with external academic institutions to design and implement experiments to aid in candidate selection and characterization for the staphylococcus aureus a program.

• Probed the ability of immune cells to elicit effector function for development of novel Fc engineering platforms and in support of numerous portfolio projects using antibody purification, protease digests, ELISA, cell-based immune killing assays (ADCC, ADCP and CDC), SDS-PAGE and western blotting, alpha screens, and related methodologies. MERCK & CO. INC. (Contracted by Eurofins Scientific) 2009 - 2012 Biochemist I, Vaccines Analytical Development West Point, PA. 2011 - 2012

• Developed a novel assay for a characterization data package to assess solubility of vaccine antigen under various conditions through centrifugation, ELISA, and western blots.

• Oversaw and ran a GMP formal stability study in collaboration with Merck Manufacturing Division to assess antigen stability over time.

• Assisted in the validation of a critical ELISA measuring antigen binding implemented in manufacturing release of final vaccine products.

Biologist I, Vaccines Basic Research West Point, PA. 2009 - 2011

• Developed and optimized a high through-put functional imaging assay measuring the target neutralizing ability of antibodies induced by vaccine candidates.

• Led the transfer of the assay technology to a contract research organization for use in clinical study evaluations. FOX CHASE CANCER CENTER 2008 - 2009

Associate Scientist Philadelphia, PA. 2008-2009

• Studied epigenetic alterations in oncogenes associated with kidney and ovarian cancers specifically related to promoter region methylation status utilizing reverse transcription PCR, western blots, and quantitative methylation specific PCR (Q-MSP). EDUCATION

Bachelors of Science BSc., Biology – Vertebrate Physiology, 2008 GPA 3.76 The Pennsylvania State University. State College, Pennsylvania PROFESSIONAL DEVELOPMENT

− Oncology Clinical PML Shadowing Program, 2019-2020

− Project Leadership Workshop, Flawless Project Execution (FPX), August 2019

− Mentoring Program, Consumer Products Division, Women’s Leadership Initiative (WLI), 2019-2020

− BD LSR Fortessa Operator Training Course, August 2013

− AAI Introduction to Immunology Course, July 2013

Contact this candidate